Purpose: Patients with an enlarged prostate and suspicion of prostate cancer pose a diagnostic dilemma. The prostate cancer detection rate of systematic 12-core transrectal ultrasound guided biopsy is between 30% and 40%. For prostates greater than 40 cc this decreases to 30% or less. Magnetic resonance-ultrasound fusion biopsy has shown superior prostate cancer detection rates. We defined the detection rate of magnetic resonance-ultrasound fusion biopsy in men with an enlarged prostate gland.
Materials And Methods: We retrospectively analyzed the records of patients who underwent multiparametric prostate magnetic resonance imaging followed by magnetic resonance-ultrasound fusion biopsy at our institution. Whole prostate volumes were calculated using magnetic resonance imaging reconstructions. Detection rates were analyzed with respect to age, prostate specific antigen and whole prostate volumes. Multivariable logistic regression was used to assess these parameters as independent predictors of prostate cancer detection.
Results: We analyzed 649 patients with a mean±SD age of 61.8±7.9 years and a median prostate specific antigen of 6.65 ng/ml (IQR 4.35-11.0). Mean whole prostate volume was 58.7±34.3 cc. The overall detection rate of the magnetic resonance-ultrasound fusion platform was 55%. For prostates less than 40 cc the detection rate was 71.1% compared to 57.5%, 46.9%, 46.9% 33.3%, 36.4% and 30.4% for glands 40 to 54.9, 55 to 69.9, 70 to 84.9, 85 to 99.9, 100 to 114.9 and 115 cc or greater, respectively (p<0.0001). Multivariable logistic regression showed a significant inverse association of magnetic resonance imaging volume with prostate cancer detection, controlling for age and prostate specific antigen.
Conclusions: Transrectal ultrasound guided and fusion biopsy cancer detection rates decreased with increasing prostate volume. However, magnetic resonance-ultrasound fusion biopsy had a higher prostate cancer detection rate compared to that of transrectal ultrasound guided biopsy in the literature. Magnetic resonance-ultrasound fusion biopsy represents a promising solution for patients with suspicion of prostate cancer and an enlarged prostate.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6301077 | PMC |
| http://dx.doi.org/10.1016/j.juro.2013.05.118 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Classification of self-assembled fluorescent probes and their application in cancer diagnosis.
Chem Commun (Camb)
January 2025
Key Laboratory of Chemical Biology and Molecular Engineering of Ministry of Education, Institute of Molecular Science, Shanxi University, Taiyuan 030006, P. R. China.
The high sensitivity, high selectivity, real-time monitoring capability, non-destructiveness, and versatility of small molecule fluorescent probes make them indispensable and powerful tools in bioscience research. Self-assembling fluorescent probes are a novel type of material that spontaneously assemble fluorescent dyes with specific molecules into nanoscale structures. Compared with ordinary small molecule fluorescent probes, self-assembled fluorescent probes have higher stability, selectivity, sensitivity, and temporal stability in detection.
View Article and Find Full Text PDFA Multi-Institutional Study of Magnetic Resonance/Ultrasound Fusion-Guided Nanoparticle-Directed Focal Therapy for Prostate Ablation.
J Urol
December 2024
Northwell Health, Smith Institute for Urology, Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York.
Purpose: Focal therapy aims to provide a durable oncologic treatment option for men with prostate cancer (PCa), while preserving their quality of life. Most focal therapy modalities rely on the direct tissue effect, resulting in a possible nontargeted approach to ablation. Here, we report the results of the first human feasibility trial utilizing nanoparticle-directed focal photothermal ablation for PCa.
View Article and Find Full Text PDFAdvances in Clinical Imaging of Vascular Inflammation: A State-of-the-Art Review.
JACC Basic Transl Sci
May 2024
Acute Multidisciplinary Imaging and Interventional Centre, Radcliffe Department of Medicine, University of Oxford, Oxford, United Kingdom.
Article Synopsis
- * The review highlights the advancements in noninvasive imaging methods for assessing vascular inflammation, particularly focusing on coronary atherosclerosis using techniques like CT, MRI, ultrasound, and PET imaging.
- * It discusses new technologies and biomarkers, examines the pros and cons of each imaging method, and emphasizes the potential benefits of combining different imaging techniques and using AI for better diagnosis and prognosis of conditions like coronary artery disease.
Integrated micro/nano drug delivery system based on magnetically responsive phase-change droplets for ultrasound theranostics.
Front Bioeng Biotechnol
April 2024
Department of Biomedical Engineering, School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, China.
Phase-change droplets (PCDs) are intelligent responsive micro and nanomaterials developed based on micro/nano bubbles. Subject to external energy inputs such as temperature and ultrasound, the core substance, perfluorocarbon (PFC), undergoes a phase transition from liquid to gas. This transformation precipitates alterations in the PCDs' structure, size, ultrasound imaging capabilities, drug delivery efficiency, and other pertinent characteristics.
View Article and Find Full Text PDFTransperineal Laser Ablation (TPLA) Treatment of Focal Low-Intermediate Risk Prostate Cancer.
Cancers (Basel)
April 2024
Diagnostic Imaging and Interventional Radiology Policlinico Tor Vergata, Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy.
This interventional pilot study aimed to evaluate the short-term (3 years) efficacy of focal laser ablation (FLA) in treating the index lesion of low-intermediate-risk prostate cancer, along with assessing the safety of the procedure (ClinicalTrials.gov ID NCT04045756). Forty patients aged between 46 and 86 with histologically proven organ-confined prostate cancer and low-to-intermediate progression risk were included.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!